Company / Return on Assets (ROA)
BioXcel Therapeutics, Inc. Return on Assets (ROA) History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-155.6%
FY2025
5-year range
-467.0% / -51.9%
FY2022-FY2025
Trend
+66.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Return on Assets (ROA) returned to growth in FY2025 after 2 years of decline, reaching -155.6%.
Based on SEC 10-K filings.
-155.6% in FY2025 with a 3-year CAGR of -103.7%.
Improved from -224.9% to -155.6% over the past 2 years.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -103.7pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on assets (roa) increased 66.7% year-over-year.
Company context
Key Data Points
- Altman Z-Score -17.49 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -155.6% | +66.7% |
| FY2024 | -467.0% | -107.7% |
| FY2023 | -224.9% | -332.9% |
| FY2022 | -51.9% | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026